© 1999 Midwifery Today, Inc. All rights reserved.
[Editor's note: These letters first appeared in Midwifery Today Issue 51 (Networking), Autumn 1999.]
I was compelled to write after reading the articles on misoprostol in the Spring 1999 issue because I was horrified that midwives are advocating the use of this drug for induction of labour when it hasn't been approved by the FDA for this purpose (according to Marsden Wagner). Haven't we as midwives been (and still are) fighting obstetrical practise that is not based on scientific data or randomised controlled trials? This concerns me greatly.- Leigh Evans, Queensland, Australia
| Issue 51|
Theme: Fathers in Pregnancy and Birth
In the Spring 1999 issue of Midwifery Today, both Jennifer Enoch and I had articles on the dangers of Cytotec (misoprostol) induction. We both mentioned evidence in the literature that suggests the possibility of increased uterine rupture associated with Cytotec induction.
The next month after this issue was published, the June 1999 issue of the American Journal of Obstetrics and Gynecology published the article "Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section." The data in this article are truly frightening. "Uterine rupture occurred in five of eighty-nine patients with previous cesarean delivery who had labor induced with misoprostol. The uterine rupture rate for patients attempting vaginal birth after cesarean was significantly higher in those who received misoprostol, 5.6 percent, than in those who did not, 0.2 percent or 1 in 423, p=0.0001)." Furthermore, a medical records review turned up several more cases of uterine rupture associated with using Cytotec with VBAC not included in their calculations.
Be clear on what this says. Over five percent of women given Cytotec for VBAC had a ruptured uterus, a 28-fold increase over those who did not have Cytotec induction for VBAC. This is a truly shocking rate of uterine rupture. And one of the five women with uterine rupture ended up with a dead baby as a result of the rupture.
Just in case you think this paper reports an aberration, the same issue of this journal has a second paper in which three of eighty-one women receiving Cytotec for a VBAC had uterine rupture—a still shocking rate of 3.7 percent. And one of the three babies died in the NICU after the rupture. Both these papers were retrospective which means that none of the women given Cytotec were part of a research project. Thus, none had received the protection of research subjects, including information on the experimental nature of the drug given to them. So in these two papers, of 170 women given Cytotec for induction with VBAC, eight have lost their uterus and two lost a baby as well. It is my educated guess that to this day none of them has been told that they were given a drug for a purpose not approved by the FDA nor has been told their case is described in published papers saying this drug should not be used in this way.
These women and babies paid a very big price because their practitioners were willing to use a very powerful drug before it has been approved by the FDA for this purpose and before it was adequately evaluated by prospective, controlled research. Hopefully, no midwife will ever be involved in any birth where Cytotec is used for VBAC and all midwives will do everything possible to prevent the use of Cytotec for any type of induction until we have more complete evaluation.
- Marsden Wagner MD, MSPH, Washington, D.C.
| Issue 49|
Theme: Bridging the Gap
A thorough look at the use of misoprostol (Cytotec) gives readers some very compelling things to think about.
- Enoch, J. (1999). Misoprostol (Cytotec): A new method of inducing labor. Midwifery Today, Issue 49: 22 - 30.
- Wagner, M. (1999). Misoprostol (Cytotec) for labor induction: a cautionary tale. Midwifery Today, Issue 49: 31 - 33.
- Plaut, M. et al. (1999, June). Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. American Journal of Obstet Gynecol: 1335 - 42.
- Blanchette, H. et al. (1999, June). Comparison of the safety and efficacy of intravaginal misoprostol (prostaglandin E1) with those of dinoprostone (prostaglandin E2) for cervical ripening and induction of labor in a community hospital. American Journal of Obstet Gynecol.
- Misoprostol: More on the dangers of Cytotec
- Misoprostol (Cytotec) for Labor Induction: A Cautionary Tale - by Marsden Wagner
- Technology in Birth: First Do No Harm - by Marsden Wagner
- Drugs in Labour - by Beverley Lawrence Beech
- Forced Labor - by David Goodman (Mother Jones magazine)
- Epidemics: Epidural, Ultrasound, Cytotec and More (Audio Tape)
- Serving Women in Hospital Birth 5: Dealing with Consumer Demand (Audio Tape)
- Midwifery Today Issue Number 49
- Midwifery Today Issue Number 51
- Midwifery Today Issue Number 57
If you enjoyed this article, you'll enjoy Midwifery Today magazine! Subscribe now!